Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Rapport Therapeutics, Inc. ( (RAPP) ) has shared an update.
On June 17, 2025, Rapport Therapeutics, Inc. held its Annual Meeting of Stockholders where key decisions were made regarding the company’s leadership and financial oversight. The stockholders elected Reid Huber, Ph.D., John Maraganore, Ph.D., and Wendy B. Young, Ph.D. as Class I directors to serve until 2028, and ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (RAPP) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Rapport Therapeutics, Inc. stock, see the RAPP Stock Forecast page.
Spark’s Take on RAPP Stock
According to Spark, TipRanks’ AI Analyst, RAPP is a Neutral.
Rapport Therapeutics, Inc. faces significant challenges with no revenue and substantial operational losses despite strong equity financing and low leverage. Technical indicators point to a downward trend, and valuation is difficult to ascertain. Positive clinical trial results offer some optimism, but leadership changes contribute to uncertainty.
To see Spark’s full report on RAPP stock, click here.
More about Rapport Therapeutics, Inc.
Average Trading Volume: 209,619
Technical Sentiment Signal: Sell
Current Market Cap: $408.8M
For detailed information about RAPP stock, go to TipRanks’ Stock Analysis page.